#United States #New York #Phantom Neuro #Connor Glass #BioFuture 2025

Phantom Neuro CEO Connor Glass to Speak at BioFuture™ 2025

The world of neurotechnology is abuzz with excitement as Dr. Connor Glass, the CEO and founder of Phantom Neuro, prepares for a significant presentation at BioFuture™ 2025. This prestigious conference, organized by Demy-Colton, will take place in New York City from October 13 to 15, 2025.

Phantom Neuro has made a name for itself as a pioneering entity specializing in advancements in human-machine interfaces. Throughout the conference, leaders from biotechnology, pharmaceuticals, digital medicine, TechBio, and related fields will converge to discuss how contemporary policies, technological innovations, and capital market dynamics are reshaping the entire healthcare landscape.

Spotlight Panel on CNS Health

On October 13 at 11:00 AM, Dr. Glass will participate in a Spotlight Panel session titled "Rewiring Minds: Breakthroughs in Brain CNS Health". This session will take place on the 12th floor of Cure, located at 345 Park Ave S, New York, NY 10010. The webinar is expected to attract a diverse audience, including healthcare innovators, investors, and policymakers, all eager to hear insights on the latest developments in neurotechnology.

The panel will be moderated by Ginger Johnson, the Senior Vice President of Lumanity. Other prominent participants include:
- Adam Rogers, CEO of NervGen Pharma
- Arun Swaminathan, CEO of Coya Therapeutics, Inc.
- Brent Vaughan, CEO and Founder of Eratos Therapeutics
- Beth Hoffman, CEO of Origami Therapeutics, Inc.

Achievements and Growth of Phantom Neuro

Phantom Neuro has seen remarkable growth this year. The company received FDA Breakthrough Device and TAP Designations, positions that underline its commitment to innovation and regulatory compliance. Furthermore, Phantom Neuro has secured additional funding and established a strategic partnership with Ottobock, a European leader in medical and industrial robotic technologies.

In addition to these accomplishments, it recently published a peer-reviewed white paper that highlights the findings of its proprietary Phantom X platform. This study emphasizes intuitive and functional prosthetic control aimed at real-world usability, a breakthrough that could revolutionize the way patients interact with prosthetic technologies.

About Phantom Neuro

Founded on innovative research initially developed at the Johns Hopkins University School of Medicine, Phantom Neuro’s mission revolves around creating a minimally invasive interface for effortless control of prosthetic limbs and robotic exoskeletons. The company has attracted investments from notable firms such as Blackrock Neurotech, Breakout Ventures, Draper Associates, LionBird Ventures, and Time BioVentures.

While the headquarters is located in Austin, Texas, Phantom Neuro is supported by an esteemed advisory board comprising experts from CTRL-Labs, D.A.R.P.A., Johns Hopkins University, and Precision Neuro. This strong foundation not only reinforces the company’s credibility but also propels its mission forward.

As Dr. Connor Glass takes the stage at BioFuture™ 2025, the anticipation is high for what promises to be an engaging and enlightening discussion on the future of neurotechnology. Those interested in watching the panel are encouraged to register and participate, as Dr. Glass and other leaders navigate the next steps in the evolution of brain health and robotic integration.

For more information about Phantom Neuro and their groundbreaking work, please visit their official website at www.phantomneuro.com.